Pires Patrícia C, Rodrigues Márcio, Alves Gilberto, Santos Adriana O
Faculty of Pharmacy (FFUC-UC), University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.
Health Sciences Research Centre (CICS-UBI), University of Beira Interior, Avenida Infante D. Henrique, 6200-506 Covilhã, Portugal.
Pharmaceutics. 2022 Mar 8;14(3):588. doi: 10.3390/pharmaceutics14030588.
Intranasal administration is a promising route for brain drug delivery. However, it can be difficult to formulate drugs that have low water solubility into high strength intranasal solutions. Hence, the purpose of this work was to review the strategies that have been used to increase drug strength in intranasal liquid formulations. Three main groups of strategies are: the use of solubilizers (change in pH, complexation and the use cosolvents/surfactants); incorporation of the drugs into a carrier nanosystem; modifications of the molecules themselves (use of salts or hydrophilic prodrugs). The use of high amounts of cosolvents and/or surfactants and pH decrease below 4 usually lead to local adverse effects, such as nasal and upper respiratory tract irritation. Cyclodextrins and (many) different carrier nanosystems, on the other hand, could be safer for intranasal administration at reasonably high concentrations, depending on selected excipients and their dose. While added attributes such as enhanced permeation, sustained delivery, or increased direct brain transport could be achieved, a great effort of optimization will be required. On the other hand, hydrophilic prodrugs, whether co-administered with a converting enzyme or not, can be used at very high concentrations, and have resulted in a fast prodrug to parent drug conversion and led to high brain drug levels. Nevertheless, the choice of which strategy to use will always depend on the characteristics of the drug and must be a case-by-case approach.
鼻内给药是一种很有前景的脑内药物递送途径。然而,将低水溶性药物制成高浓度鼻内溶液可能具有挑战性。因此,这项工作的目的是回顾用于提高鼻内液体制剂中药物浓度的策略。主要有三类策略:使用增溶剂(改变pH值、络合以及使用助溶剂/表面活性剂);将药物掺入载体纳米系统;对分子本身进行修饰(使用盐类或亲水性前药)。使用大量助溶剂和/或表面活性剂以及将pH值降至4以下通常会导致局部不良反应,如鼻腔和上呼吸道刺激。另一方面,根据所选辅料及其剂量,环糊精和(许多)不同的载体纳米系统在合理的高浓度下用于鼻内给药可能更安全。虽然可以实现诸如增强渗透、持续递送或增加直接脑内转运等附加特性,但仍需要付出巨大的优化努力。另一方面,亲水性前药,无论是否与转化酶共同给药,都可以在非常高的浓度下使用,并已实现前药向母体药物的快速转化,从而使脑内药物水平升高。然而,选择使用哪种策略总是取决于药物的特性,必须采取个案处理的方法。